As regular readers know, I believe the 340B Drug Pricing Program needs to evolve into a more transparent, properly regulated program.
That’s why I’m especially glad to share today’s guest post from Jeremy Docken, Founder and CEO at Kalderos. Jeremy explains the 340B program's use of rebates instead of the more common upfront discounts. He argues that greater adoption of the established 340B rebate process will benefit all stakeholders: covered entities, manufacturers, state Medicaid programs, and others.
To help the industry learn more about 340B rebates, Kalderos is sponsoring a live video webinar: Evolving 340B: Moving from Discounts to Rebates.
I’ll be joining Jeremy during this webinar for an interactive presentation, discussion, and Q&A. This webinar will take place on September 11, 2020 (12:00 p.m. to 1:00 p.m. ET). Registration is free and open to all.
Read on for Jeremy’s insights—and be sure to join us in three weeks!
Regards,
Adam
Read more »
Source: Post feed
